By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it generated no revenues for the first quarter of 2011, compared to $125,000 for the first quarter of 2010.

The Tel Aviv, Israel-based firm, which makes computational biology tools and is developing therapeutics, reported a net loss of $1.9 million, or $.06 per share, for the three-month period ended March 31. For Q1 2010, its net loss was $2.7 million, or $.08 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.